💊 GLP-1 Drugs
Retatrutide — The Triple Agonist Drug That Causes 24% Weight Loss (2026)
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) showing 24% weight loss in Phase 2 trials — the most powerful weight loss drug in development. Updated January 2026.
Key Takeaways
- Retatrutide produced average 24.2% weight loss in Phase 2 trials — more than any approved drug
- It targets three receptors — GLP-1, GIP, and glucagon — Mounjaro only targets two
- Phase 3 trials (TRIUMPH programme) are currently recruiting
- If approved, retatrutide could become the most effective anti-obesity drug ever approved
- Expected FDA/MHRA submission: 2026–2027 if Phase 3 succeeds
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational once-weekly injectable medication developed by Eli Lilly. Unlike current drugs, it is a triple agonist — simultaneously activating three gut hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple mechanism produces additive effects on appetite suppression, energy expenditure, and fat metabolism.
24.2%
Average weight loss at 48 weeks (Phase 2, highest dose)
3
Receptors activated vs Mounjaro's 2 vs Ozempic's 1
2027
Estimated potential FDA approval if Phase 3 succeeds
Phase 2 Trial Results
| Dose | Weight Loss at 24 wks | Weight Loss at 48 wks | ≥15% loss |
|---|
| Placebo | 2.1% | 2.1% | 2% |
| 4mg weekly | 8.7% | 17.5% | 46% |
| 8mg weekly | 12.9% | 22.8% | 67% |
| 12mg weekly | 17.5% | 24.2% | 83% |
Why the Glucagon Receptor Matters
Adding glucagon receptor agonism to GLP-1 and GIP is the key innovation. Glucagon activates brown adipose tissue (BAT) thermogenesis — directly increasing energy expenditure. It also promotes hepatic fat breakdown (lipolysis) and reduces liver fat. This adds a metabolic calorie-burning component that GLP-1/GIP drugs alone lack — explaining the additional weight loss versus tirzepatide (Mounjaro).
Comparison: Current Drug Landscape
| Drug | Mechanism | Best Weight Loss | Status |
|---|
| Ozempic/Wegovy (Semaglutide) | GLP-1 | 15–17% | Approved |
| Mounjaro/Zepbound (Tirzepatide) | GLP-1 + GIP | 20–22% | Approved |
| Retatrutide | GLP-1 + GIP + Glucagon | 24%+ | Phase 3 |
| CagriSema (Cagrilintide + Sema) | GLP-1 + Amylin | ~25% | Phase 3 |
ℹ️ When Will Retatrutide Be Available?
Phase 3 TRIUMPH trials are underway. If results confirm Phase 2 data, Eli Lilly could file for FDA approval in 2026–2027 with a potential launch in 2027–2028. UK MHRA approval would follow. Until then, tirzepatide (Mounjaro) remains the most effective approved option.
Frequently Asked Questions
How does retatrutide compare to Mounjaro?▼
Retatrutide produced 24.2% weight loss vs Mounjaro's 20–22% at the highest doses. The additional glucagon receptor agonism increases energy expenditure through thermogenesis — providing extra weight loss beyond dual GLP-1/GIP stimulation. However, these are Phase 2 comparisons; head-to-head Phase 3 data is needed.
What are retatrutide side effects?▼
Phase 2 trial: similar GI profile to other GLP-1 drugs — nausea (42%), vomiting (22%), diarrhoea (18%), constipation (21%). Discontinuation rate was 16% at highest dose vs 3% placebo. The glucagon component may cause slightly more nausea. Full Phase 3 safety data will clarify the long-term profile.
Can I get retatrutide now?▼
No — retatrutide is not approved anywhere in the world. It is in Phase 3 clinical trials. Clinical trial participation may be possible — search ClinicalTrials.gov for 'retatrutide' to find recruiting studies in your region. Currently approved alternatives: semaglutide (Wegovy) and tirzepatide (Mounjaro/Zepbound).
Related Health Guides
⚕️ Medical Disclaimer: For informational purposes only. Always consult a qualified healthcare professional before starting or changing any medication or treatment.
PS
Consultant Endocrinologist
All articles reviewed by qualified healthcare professionals following NHS, AHA, and WHO guidelines.